Ambu A/S Reports Strong Q1 2024/25 Results

Ambu A/S Class B ( (AMBFF) ) has released its Q1 earnings. Here is a breakdown of the information Ambu A/S Class B presented to its investors.

Ambu A/S, a leading company specializing in single-use endoscopy, anaesthesia, and patient monitoring solutions, has reported robust financial results for the first quarter of the 2024/25 financial year. The company, headquartered in Denmark, is known for its innovative medical technology products and a strong commitment to sustainability.

In the first quarter of the fiscal year, Ambu achieved an impressive 19.5% organic revenue growth and a 16.1% EBIT margin before special items. This growth was largely driven by significant advances in their Endoscopy Solutions and Anaesthesia & Patient Monitoring segments. Notably, Endoscopy Solutions saw a 20.6% increase, while Anaesthesia & Patient Monitoring grew by 17.8%, benefiting from strategic price adjustments and increased sales volumes.

Key financial highlights for the quarter include a revenue increase to DKK 1,510 million, up from DKK 1,254 million in the previous year, and a substantial improvement in EBIT from DKK 126 million to DKK 243 million. Additionally, Ambu’s strategic moves included the registration of a new video laryngoscopy solution and the commercial launch of a ureteroscopy product, both contributing to the company’s growth trajectory. On the sustainability front, the company has made strides by implementing bioplastic materials in all marketed endoscope handles, underscoring its commitment to environmentally friendly practices.

Looking forward, Ambu has upgraded its financial guidance for the full year, now expecting organic revenue growth of 11-14% and an EBIT margin of 13-15% before special items. The company remains focused on launching innovative products and driving sustainable practices, which are expected to support continued growth and profitability.